MELBOURNE, Australia, Oct. 11, 2020 (GLOBE NEWSWIRE) — Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive
retinal diseases, today announces the launch of its initial public offering (the “Offering”) of American Depositary Shares (“ADS”), each of which will represent eight of the Company’s ordinary